Phase I trial shows safety of investigational drug in treating chronic lymphocytic le
 

Reporting results from a first-in-human phase I clinical trial, researchers at University of California San Diego School of Medicine have found that treatment with cirmtuzumab, an experimental monoclonal antibody-based drug, measurably inhibited the "stemness" of chronic leukemia cancer cells - their ability to self-renew and resist terminal differentiation and senescence.

More...

Re: Phase I trial shows safety of investigational drug in treating chronic lymphocyti
 

at asco:
https://meetinglibrary.asco.org/record/161802/abstract
Authors:
Tejal Amar Patel, Joe Ensor, Angel Augusto Rodriguez, Anna Belcheva, Jorge German Darcourt, Polly Ann Niravath, John G. Kuhn, Virginia G. Kaklamani, Xiaoxian Li, Toniva Boone, Jenny Chee Ning Chang; Methodist Cancer Center, Houston, TX; Houston Methodist Hospital, Houston, TX; Houston Methodist Cancer Center, Houston, TX; Baylor College of Medicine, Houston, TX; The University of Texas Health... View More
Abstract Disclosures
Background:
Based on our preclinical data, we conducted a phase I study oftrastuzumab-emtansine (T-DM1) in combination with Lapatinib and Nab-paclitaxel in patients with HER2 over-expressed stage IV breast cancer.
Methods:
Phase Ib study was conducted using 3+3 dose de-escalation design, with TDM1 with Lapatinib and nab-paclitaxel administered for a total of 4 cycles. Primary purpose was to evaluate the maximum tolerated dose (MTD) of T-DM1 with Lapatinib and Nab-paclitaxel. Safety, tumor response and pharmacokinetics (PK) were also assessed. Dose limiting toxicities (DLTs) were defined as ≥ grade 3 non hematological toxicity attributed to the study drugs. Key inclusion criteria were stage IV HER2 positive breast cancer, LVEF ≥ 45%, and peripheral neuropathy < grade 2.
Results:
The MTD was T-DM1 3.0 mg/kg every 3 weeks along with Lapatinib 750mg oral daily and Nab-paclitaxel 80mg/m2 weekly. Twenty four patients, median age 50 (47.9-55.9) years were enrolled. The dose limiting toxicities were diarrhea and elevated liver function tests. At MTD, 42.9% (6/14) experienced grade 3 or higher toxicity. Fourteen patients with median of 1 (range 0-5) prior metastatic treatments were evaluable for response. 12 patients (85.7%) had an objective response including 6 CR and 2 PR. T-DM1 pharmacokinetics was unaffected by Lapatinib.
Conclusions:
T-DM1 with Lapatinib and Nab-paclitaxel therapy was relatively well tolerated with significant anti-tumor activity observed. Clinical trial information: NCT02073916